Roche Korea's oral 5q spinal muscular atrophy treatment Evrysdi Dry Syrup has been recognized for its benefits and has crossed the insurance threshold. The HIRA released the results of the '2023 6th Pharmaceutical Reimbursement Evaluation Committee' deliberation on the 1st.
Ace Pharma's Megval 50mg and H.I.Pharm's Melpspal 50mg, both of which are Evrysdi and Melphalan Hydrochloride-component multiple myeloma treatments, were all approved for reimbursement. Evrysdi is a liquid formulation that is taken orally once a day and can be applied to patients who have difficulty in spinal treatment. The effect of improving motor function and the safety profile was confirmed in patients with a wide range of disease types, in